{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:34:28Z","timestamp":1790814868070,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Pharmaceutical K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the THOR trial (NCT03390504) Cohort 1, erdafitinib demonstrated significantly prolonged overall survival (OS) (median 12.1 versus 7.8\u00a0months) and reduced risk of death by 36% (hazard ratio 0.64, P\u2009=\u20090.005) compared with chemotherapy in metastatic urothelial carcinoma (mUC) patients with <jats:italic>FGFR<\/jats:italic> alterations who progressed after\u2009\u2265\u20091 prior treatments, including anti-PD-(L)1. There have been no reports of the Japanese subgroup results yet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>THOR Cohort 1 randomized patients to erdafitinib once daily or docetaxel\/vinflunine once every 3\u00a0weeks. Primary endpoint was OS. Secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). No specific statistical power was set for this Japanese subgroup analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 266 patients randomized, 27 (14 erdafitinib; 13 chemotherapy) were Japanese. Baseline characteristics were generally similar between treatments and to the overall population, except for more males, lower body weight, and more upper tract primary tumors among Japanese patients. Compared with chemotherapy, erdafitinib showed improved OS (median 25.4 versus 12.4 months), PFS (median 8.4 versus 2.9\u00a0months) and ORR (57.1% versus 15.4%). Any grade treatment-related adverse events (AEs) occurred in all patients from both arms but Grade 3\/4 AEs and AEs leading to discontinuation were lower in the erdafitinib arm. No new safety signals were observed in the Japanese subgroup.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the Japanese subgroup, erdafitinib showed improved survival and response compared to chemotherapy, with no new safety concerns. These results support erdafitinib as a treatment option for Japanese mUC patients with <jats:italic>FGFR<\/jats:italic> alterations, and early <jats:italic>FGFR<\/jats:italic> testing after diagnosis of mUC should be considered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-024-02583-3","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T10:01:58Z","timestamp":1721210518000},"page":"1516-1527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations"],"prefix":"10.1007","volume":"29","author":[{"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Toyoizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutapa","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Deprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"2583_CR1","unstructured":"Kaseb H, Aeddula N Bladder Cancer. [Updated 2022 Oct 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536923\/. Accessed 19 Oct 2023"},{"issue":"6","key":"2583_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Jubber I, Black PC et al (2018) Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur Urol 74(6):784\u2013795. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.001","journal-title":"Eur Urol"},{"issue":"9","key":"2583_CR3","doi-asserted-by":"publisher","first-page":"A419","DOI":"10.1016\/j.jval.2017.08.127","volume":"20","author":"M Bharmal","year":"2017","unstructured":"Bharmal M, Guenther S, Kearney M (2017) Epidemiology of locally advanced or metastatic urothelial cancer in the US Europe and Japan. Value Health 20(9):A419. https:\/\/doi.org\/10.1016\/j.jval.2017.08.127","journal-title":"Value Health"},{"key":"2583_CR4","unstructured":"National cancer center in-hospital cancer registries nationwide tally [In Japanese]. Available at: https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_registry.html. Accessed 21 Nov 2023"},{"key":"2583_CR5","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.2147\/cmar.S231508","volume":"12","author":"C Fischer","year":"2020","unstructured":"Fischer C, Hofmann R, Hegele A (2020) Chemotherapy of locally advanced or metastatic urothelial cell carcinoma: monocentric real-life data. Cancer Manag Res 12:5077\u20135084. https:\/\/doi.org\/10.2147\/cmar.S231508","journal-title":"Cancer Manag Res"},{"key":"2583_CR6","unstructured":"National cancer center in-hospital cancer registry survival rate aggregation. Available at: https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_reg_surv\/index.html. Accessed 21 Nov 2023"},{"key":"2583_CR7","unstructured":"The Japanese urological association (Bladder cancer treatment guidelines (2019 edn). Available at: https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/39_bladder_cancer_2019_rev2021_info.pdf. Accessed 21 Nov 2023"},{"issue":"11","key":"2583_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"New Engl J Med"},{"issue":"12","key":"2583_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. New Engl J Med 384(12):1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"New Engl J Med"},{"issue":"6","key":"2583_CR10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1158\/1535-7163.Mct-16-0589","volume":"16","author":"TPS Perera","year":"2017","unstructured":"Perera TPS, Jovcheva E, Mevellec L et al (2017) Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mole Cancer Ther 16(6):1010\u20131020. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0589","journal-title":"Mole Cancer Ther"},{"issue":"11","key":"2583_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1541-7786.Mcr-10-0168","volume":"8","author":"EM Haugsten","year":"2010","unstructured":"Haugsten EM, Wiedlocha A, Olsnes S et al (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mole Cancer Res: MCR 8(11):1439\u20131452. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-10-0168","journal-title":"Mole Cancer Res: MCR"},{"issue":"1","key":"2583_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/14796694.4.1.71","volume":"4","author":"MA Knowles","year":"2008","unstructured":"Knowles MA (2008) Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol (London, England) 4(1):71\u201383. https:\/\/doi.org\/10.2217\/14796694.4.1.71","journal-title":"Future Oncol (London, England)"},{"issue":"1","key":"2583_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.juro.2014.06.026","volume":"193","author":"R Turo","year":"2015","unstructured":"Turo R, Harnden P, Thygesen H et al (2015) FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases. J Urol 193(1):325\u2013330. https:\/\/doi.org\/10.1016\/j.juro.2014.06.026","journal-title":"J Urol"},{"issue":"2","key":"2583_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11934-015-0566-y","volume":"17","author":"Q Li","year":"2016","unstructured":"Li Q, Bagrodia A, Cha EK et al (2016) Prognostic genetic signatures in upper tract urothelial carcinoma. Curr Urol Rep 17(2):12. https:\/\/doi.org\/10.1007\/s11934-015-0566-y","journal-title":"Curr Urol Rep"},{"issue":"4","key":"2583_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH et al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. New Engl J Med 381(4):338\u2013348. https:\/\/doi.org\/10.1056\/NEJMoa1817323","journal-title":"New Engl J Med"},{"key":"2583_CR16","unstructured":"U.S. Food and Drug Administration FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma. Accessed 17 Oct 2023"},{"key":"2583_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH et al (2023) Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. New Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2308849","journal-title":"New Engl J Med"},{"issue":"3","key":"2583_CR18","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cam4.5165","volume":"12","author":"N Matsubara","year":"2023","unstructured":"Matsubara N, Yonese J, Kojima T et al (2023) Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med 12(3):2761\u20132771. https:\/\/doi.org\/10.1002\/cam4.5165","journal-title":"Cancer Med"},{"issue":"11","key":"2583_CR19","doi-asserted-by":"publisher","first-page":"e1916091","DOI":"10.1001\/jamanetworkopen.2019.16091","volume":"2","author":"CLM de Almeida","year":"2019","unstructured":"de Almeida CLM, de Oliveira SAS, Haslam A et al (2019) Estimation of percentage of patients with fibroblast growth factor receptor alterations eligible for off-label use of erdafitinib. JAMA Netw Open 2(11):e1916091\u2013e1916091. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16091","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2583_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25\u201341. https:\/\/doi.org\/10.1038\/nrc3817","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2583_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2022.1167","volume":"8","author":"V Nimgaonkar","year":"2022","unstructured":"Nimgaonkar V, Hubbard RA, Carpenter EL et al (2022) Biomarker testing, treatment uptake, and survival among patients with urothelial cancer receiving gene-targeted therapy. JAMA Oncol 8(7):1070\u20131072. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1167","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02583-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:11:05Z","timestamp":1727068265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02583-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2583"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02583-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nobuaki Matsubara has received grants or contracts from Janssen Pharmaceutical K.K., MSD K.K., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Bayer AG, Amgen K.K., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Roche\/Genentech, Seagen, Novartis Pharma K.K., and AbbVie Inc.; consulting fees from Sanofi K.K., Janssen Pharmaceutical K.K., AstraZeneca K.K., Eli Lilly Japan K.K., Amgen K.K., Seagen, and Pfizer Japan Inc.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi K.K.. Yuji Miura has received grants or contracts from MSD and Ono Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eisai Co. Ltd., Ono Pharmaceutical Co., Ltd., and MSD. Hiroyuki Nishiyama has received grants or contracts from Ono Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD, Astellas Pharma Inc., Merck Biopharma Co. Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., and Nippon Fine Chemical Co., Ltd..; other financial or non-financial interests from Bayer Yakuhin, Ltd Rikiya Taoka and Nobuaki Shimizu report no conflicts of interest. Takahiro Kojima has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas Pharma Inc. Jason Hwang reports employment and employee stock ownership from Janssen Pharmaceutical K.K.; Tatsuya Ote reports employment from Janssen Pharmaceutical K.K., and employee stock ownership from Janssen Pharmaceutical K.K., and Johnson & Johnson. Ryo Oyama reports employment and employee stock ownership from Janssen Pharmaceutical K.K. Kiichiro Toyoizumi reports employment from Janssen Pharmaceutical K.K., and employee stock ownership from Johnson & Johnson. Sutapa Mukhopadhyay, Spyros Triantos, and Kris Deprince report employment from Janssen Research & Development, and employee stock ownership from Johnson & Johnson. Yohann Loriot has received grants or contracts from Janssen Oncology, MSD Oncology, AstraZeneca, Exelixis, Incyte, Pfizer Japan Inc., Sanofi K.K., Seagen, Astellas Pharma Inc., Gilead Sciences Inc., Merck KGaA, Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Roche, and Tyra Biosciences; consulting fees from Janssen Pharmaceutical Co. Ltd., Astellas Pharma Inc., Roche, AstraZeneca, MSD Oncology, Seagen, Bristol-Myers Squibb, Taiho Pharmaceutical Co., Ltd., Loxo\/Lilly, Pfizer\/EMD Serono, Merck KGaA, Gilead Sciences, Pfizer Japan Inc., Roche, MSD Oncology; support for attending meetings and\/or travel from Astellas Pharma, Janssen Oncology, Roche, MSD Oncology, AstraZeneca, and Seagen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}